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Low heart rale variability predicts increased mortality after 
wte myocardial infarction (1.2) in patienls with coronary 
utery diseass (3). Beta-adrenergic blocking agents augment 
Iearl rale variability in healthy subjecis (4) and atIer acute 
nyocardial infarction (S), but it is not known whether beta- 
Ilockers mcdiiy variation in heart tale and its diurnal rhythm in 
?alienls with uncomplicated coronary anery disease. 
Published results of the etTects of different beta-blockers 
n postinfarction patients clearly thaw a beneficial effecr of 
ipophilic beta-blockers with regard ID reduction in sudden 
iealhs and ventricular fibrillation (6). However. a similar 
:ffect has nor been rewrted for hvdroohilic blackers. The 
wme pattern with r&d lo sudden c&Jiic death has also 
been reported for primary prevention in hypertension (6). 
The mechanisms involved in beta-blcckerinduced preven- 
lion of ventricular fibrill tion are not clear. Results obtained in 
conxiws pigs s~sl tbrd tlte effect invdver beta-bbckak 
tml only in the heart but also in the brain (7,ll). It has been 
Dmposed (9.10) that beta-bkxkwk in the cmtmI nwvcw 
iysiem causes alunwion d the withdrawal of vagd tar IO 
the hea% which occurs in stress sitwtimx with increased 
sympatbctk cutlow fmm the central netvow system (I I). 
lltere is slmru cxocrimattal cvidcttce tbat P better mpin- 
iaid vagal tone&n&ted with P reduced sympathetic tone 
in the heart implies reduced risk for ventricular fibrillation 
(12). It is therefore imwrlaat lo studv whether betahlocken 
exert such a dual &ion on cat&c autonomic nervw 
control. 
Our aim was to assess the effect of beta-blocker therapy 
on heart rate variability in patients with comnary artery 
disease using both time and frequency domain measures of 
heart period variability. In addition. our purpose was to 
evaluate whether the effects of a lipophilii b&-blocker 
~mempmlol). with a higher degree of central nervous system 
distribution. diier from those of a nonlipophilic beta-blocker 
(atendol). 
Methods 
FalIeols. We studied I8 male patients (mean age 54 
years) with uncomplicated coronary artery disuse referred 
for elective coronary an&gaphy because of disabling an- 
ginal chest pain. The entry criteria were male patients wirh 
stable coronary tier, disease and age ranging from 18 to 75 
yews. Patient exclusion criteria were I) hts!ory d my~c;ir- 
dial infarction within the past 6 mnan$. 2) clinical heart 
failure. 3) severe hyperIension, 4) renal failure, 5) chronic 
obstructive pulmonary disease, 6) severe peripheral vascular 
disease, 7) diabetes mellitus, 8) other severe systemic dis- 
ease, 9) atria1 fibrillation, IO) bundle branch block, Ii) 
alcohol abuse, 12) pardcipation in other randomizea trials 
during the past month, 13) need for concomitant can&active 
therapy, except long- or short-acting nitrates. and 14) unwill- 
ingness to participate. Left-sided cardiac catheterization was 
perfomted within 2 months after the double-blind trratment 
It revealed significant stenosis (>SO%) of the left main artery 
in three patients, three-vessel disease in seven. twcwes~el 
disease in four and single-vessel disease in seven patients. 
Mean ejection fraction in the patients was 72.1 - 11.4%. 
Three patients had a history of non-Q wwe myocardial 
infarction, and four patients had a history of Q-wave myo- 
cardial infarction (one anterior. ~“e iatenl and two inferior). 
Shdy pm~oml. The study was of double-blind, rdndam- 
ized. placebo-contmlled, three-period cuxso~er design. Pa- 
tients considered to b-e potential study candidates were 
asked to attend a screening visit. After giving informed 
consent. they were screened by full medical history. physi- 
cal examination, standard laboratory tests ;md a 12.lead 
electmcadiogram (ECG). Before the mndumizatio”. cal- 
cium antagonists and other cardioactive medications (except 
nitrates) were discontinued. Former beta-blocker therapy 
was discontinued at the start of the double-blind treatment 
wicd. Patients who were in clinically stable condition. met 
h inelusion criteria and had no e&siu” criteria were 
randomized for doubleblind treatment with 200 mg of con- 
bulled-release metoprolol, IO0 mg of atenolol or placebo 
given once daily in the morning. Treatment periods lasted 
2 weeks each and were not separated by washout periods. 
Thus. the randomized phase of the study lasted 6 weeks. 
Two hundred milliitwrts of metopmlol was administered 
BJ two conbulled-release meto+xolol tablets of ICil mg each. 
During the a~eenolol treatment perid. patients received one 
active lfl&mg atenolol Iablet and one placebo tableI. To 
avoid withdrawal elfecls when crossing from active therapy 
to placebo. patients received one placebo and one 2S-mg 
atermlol tablet dailv durine the 1st 4 davs and two placebo 
tablets daily Ihereairer for-the rest of thk placebo p&d. 
e. Patients were allmated to treatment ac- 
cordii to a computer-generated randomization l&I. The six 
possible treatment orders were distributed at random among 
the patients in blocks of six. 
Ambalatwy ECG mord&. All patients underwent am- 
bulatory two-channel 24-h ECG recording within the last 
2 days of each treatment period. The Delmar Avionics 
elecImscanner was used for analysis of :he recordings. 
Additionally, all recordings were read marlually by one of 
the authors. The patients were instructed IO keep a diary 
during the recordii petiti, in which the exact time ofgoing 
to bed, mormng arousal and getting up was recorded. To 
discriminate the effects of arousal and change in body 
posture on the circadian rhythm of heat? rate variability. the 
patients were asked to stay in a supine position for 30 llin 
after arousal, after that they were allowed to get up during 
each of the recordings. 
Annaiysis of heart rate variability. Tlte digitally sampled 
KG data were transferred from the Delmar Avionics scan- 
ner to a microcomputer for analysis of heart period vzuiabil- 
ity. and hean rate variability was measured by a method 
described in detail elsewhere (13). A linear detrend was 
applied to the RR interval data in segments of 512 samples to 
make ii more staticmaw. This was im”lemented by Iint 
fitting a straight line to a &cent by a standard least-n&es 
method ““d the” subtracting it from the sample values. The 
computer prwam a”romatically detects and labels each 
QUS complex and filters cut the RR intervals that differ in 
durdtion bv >30% fmm the meviouslv acceoted interval. 
With this .type of filtering lechnique; abtubt temporary 
changes in RR interval sequence representing anifacts or 
ectopic beats were removed. Only segments that qualified at 
least 90% of the RR intervals were included in the final 
analysis. 
Frerw”cv domnin meawre”wnI of beart rate vsrisbilitv. 
An aut&gr&ive model was applied to estimate the power 
spectral components of the RR interval variability (14). Size 
Itl was used for the model order when analvzinn RR interval 
data. The computer program autontaticnfiy c&ulates the 
autoregressive coefficients to define the power spectral den- 
sity. Power spectra were calculated within four frequency 
bands: high frequency power. fromO.lS too.40 Hz. which is 
suggested as an index of cardiac parasympathetic activity 
(ILI7): low frequency power, from 0.04 to 0.15 Hz, which 
reflects sympathetic activity with vagal modulation; very 
low frequency power, fmm 0.0033 to 0.04 Hz; and ultralow 
frequency p&x, <0.0033 Hz. 
Time domain nteawrmnent of heart rate varlabilily. The 
wt.mean-square successive dilierence of normal RR intcr- 
vals and the standard deviation of the normal RR interval 
were measured from the oericd of the successive 512 beats. 
Both I- and 24-h average &es of heart rate variability were 
computed in the frequency and time domains. Measures of 
heart rate variability were also presented separately for 
daytime (awake. from 9 AM to IO PM) and nighttime (asleep. 
from midnight to 5 AM) hours. During morning arousal. heart 
rate variability was calculated for periods of 30 min before 
and after arousal in the supine position and immediately after 
rising to a standing position. 
Laboratory assessment. A blood sample from a cubital 
vein was collected immediately after each 24.h ECG record- 
ing for estimating the plasma concentration of the study 
drug. The samples were collected into heparinized tubes and 
centrifuged. The plasma was separated and stored at -20°C 
until analysis. 
SIalistics. A multiplicative log-normal model with the 
factors patient, period, treatment and first-order carryover 
was used. The analysis of variance, which corrects for 
period and carryover effects, was applied to the log. 
transfomwd values. Using this kind of calculation, ~eomet- 
ric means were obtained. For the comparisons betwen two 
treatments this analysis may be described as an improved 
paired t test. 
RoSUllS 
Aversgt%!-h freqwncy andtimednmeasoresofberol 
mb w&Wity. All frequency domain measures of heart 
period variability, except low freqoeocy power, were signif- 
icantly augmented by beta-blockers (Table I). Similarly, 
during hta.blockade both time domain measures of heart 
rate variability increased compared with that during placebo 
administration (Table 1). The enhancement of heart raw 
variability was comparable with both beta-blockers. With 
atenolol and controlled-release metopmlol. the mean high 
frequency power increased 64% and 62%. very low frequency 
power iocreased 4% and 38% and ultralow freqoency power 
increased 51% and 36%. nspeetively (Table I). 
Ciradhn vnrhlbo of bcarl rale v&&4iHv. Tbe circa 
of heart period variabiliiy arehisplayed in Figures 1 ;o 4 and 
Table 2. The circadian rbvihm with hieber values durinz 
nighttime hours was &o&during the p&&o period in the 
root-mean-square successive dierena of normal RR inter- 
vals and lix frequency domain lneasorcs of ke$oI period 
variability, except in ultmlow bcqocncy power (Table 2, 
Fig. 1 IO 4). The diurnal pwiodiiity of hean mtc variability 
was cat abulished by beta-blocken because they inwe& 
heart rate vhbilit~ dorios bath dwtime sod nkbttime 
hours. althoogh the- most &nifkaot biemoce co&wed 
with placebo was observed during the daytime hours (Tabks 
3 and 4). 
Elttcld~wGwalakarlrmenrhbuuy. Then 
was no sigoifkant dinence in high f-y power and the 
mom-mean~squarc of the di&ences of swxssive RR inter- 
FIgwe 1. Circadian rhythm of least squam mean 
values of high frequency (IiF) power of hean rate 
variability in patients with eoronuy artery disease. 
vals between beta.blockade and placebo BS assessed in the 
30min period before amusal (Table 5). Nevertheless. the 
quotient after/before arousal showed that high frequency 
power tended to decrease less during active therapy atIer 
amusal. compared to the placebo period (Table 6). Similar!y. 
with beta-blockers the mot-mean-square of the ditTerences 
of successive RR intervals was significantly higher after 
arousal and getting up compared to the placebo (Table 5). 
RR ltderwl unl art&l btrmd p-. The avenge 24-h 
RR intctvrd was significantly longer during beta-blockade 
(Table I). The RR interval had a circadian rhvihm durinn 
bath the bcta.blc&de and placebo periods (Table 2). The 
average systolic and diastolic blood pressures were signifi- 
cantly (p < 0.01) lower during betwblockade in both the 
supine and standing positions. 
Rssma drug conanlrs(itos. The mean plasma EOIICEII- 
traitions of arenolol and metowolol were I.197 + 550 nmoY 
liter during the atenolol petidd and 321 + 2M) nmoyl during 
the metoprulol period. 
Discussion 
Coronary artery disease and heart rate \nriabiMy. Dimin- 
ished heart rate variability is common in wronnry artery 
d&?&se (3. IY-20) and afier myocardial infarction (21-24) and 
is associated with adverse outcome in these patient groups 
(1.3). Depressed heart rate variability, PE assessed by the 
standard deviation of normal RR intervals, cwrelates inde- 
pendently with mortality after myocardial infarction (I) and 
in patients with coronary artery disease (3). Recently, the 
F¶gwe 3. Circadian rhythm of least square mean 
values of very low frequency (VLD power If heart 
rate variability in patients with coronary artery dis- 
ease. 
association between mortality and meawes of heart rate 
wiability was shown in patients after myocwdial infarction 
21). 
Et&t of beta.hlo&ers aed other audk&ivedrngsoa 
lnrt rate vavtabtlity. We showed that beta-blocker therapy 
iugmented heart rate variability in patients with caronary 
wry disease. Thus. both beta.blockers significantly in- 
xeased high frequency power spectra and the root-mean- 
muare of the differences of successive RR intervals. Power 
“the low frequency band tended to be higher with beta- 
dockers, but the difference relative to placebo was not 
dgnificant. The standard deviation of normal RR intervals 
and very low and ultralow freque”cy power, which are 
“dependent predictors of mortality in patients aftcr acute 
nywardial infarction &?I), were also significantly aug- 
nented by beta.blockers. However, the interpretation ofthe 
nechanisms of very low and ultralow frequency powers is 
Sfficult because their physiologic background is still un- 
know”. 
Our results agree with recent studies showing increased 
heart rate variability by bet”-blockade. An uncontrolled trial 
bund that high frequency power was signiticantly higher in 
patients receiving beta-blockers after acute myocardial in- 
faiction cornoared with oatients who did not 6). The studv 
with healthy s”biects showed that atenolol treatment pro- 
duced a significant (84%) increase in high frequency pwer 
and a 61% increase in the root-mean-square successive 
difference of nomml RR intervals (4). In contrast to the 
p:wnt results, they found no significant enhancement in the 
standard deviation of normal RR intervals. Only a few 
cardioactive drugs in clinical use, other than beta-blockers, 
have been shown t” enhance heart rate variability. Digitalis 
is known to have a vagotonic effect (29, and studies in 
patients with heart failure suggested increased vagal reactiv- 
ity during therapy with angiotensin-cor.verting enzyme in- 
hibitors (26,27). Calcium channel blofki”g agents do not 
seem to inflttenee heart rate variabilitv (4). and class IC 
antia&ythmic drugs have been shown ~“~rcdttce heart rate 
variability (28). 1 is “at knom whether the abiity of a 
cardiitive drug to mOaity heart rate vwiability may co”- 
tribute to the fact that beta-blockers are “we effective than 
calcium chanml blockers in dectwsing monality (29.M). 
and cllus IC antiarrhytbmii drugs may have a detrimental 
effect after acute myocardial i”farctkm (31). 
lw.hbdtathqlndrpadiu~olbartntt 
vui&Rity, Several studies have described a ciradiaa 
rhythm in the occurtwce of cardiovasetdru events (32-34). 
Accordinely. the circadian rhvthm of heart rate variability _.. 
has bee” found in healthy Objects (35) and survivors dr 
cardiac arrest (13). The& are reparts showi”g that beta- 
blocker themo~ blunts the momiM increase in BEute wdii 
vascular eve& (32.34), but the&is 110 information on the 
effect of beta.bloeken ~1 the circadii variaticm ol heart 
period variability in ccro~ly artery disease. 
We found that he~ rate variability exhibited a circadian 
patter” in patients with coronary artery disease, and that 
beta-blockers signiicantly augmented “ieas~ns of heart rate 
variability during both daytime and nighttime hours, al- 
though the statistical difference co”tparcd with placebo WBS 
stronger during the day. AS assessed by high frequency 
power. the present observation of significantly higher heart 
rate vari&iity after amusal and getting up using beta- 
blockers and the tendency of beta.blockers to decrease high 
Frequency power less than placebo after amusal may be 
important in regtd&g cardiac vulnerability in the morning. 
It may be one of the mechanisms by which beta-blockers 
offer protection fmm acute cardiovascular events. 
Mtch&msof”xdlf@gluutntevari&ty. Useof 
beta.blwkers resulted in si&icant awnentation of hi& 
frequency power and the &I-mean-sq&e successive dir- 
Table 3. Effect of Atenolol and Metopmlol WI Circadian Variation of Heart Rate Variability in 18 
Patients with Coranarv Arterv Disease louotient nizhtldav) . I I ,. 
AteFM M~klpdOl Placebo 
HF power (ms’l t.36,1.c&t.‘ll,* I.57 11.16-2.13)~ I.68 (1.%2.2.3,t 
LF power (ms? 1.63 (1.32-2.0511 1.70 I1.32-2.19k I.46 (1.03-2.W’ 
VLF power Qs’) I.16 (0.91-I.Hl 1.37 II.Ol-I&l’ 1.47 (I.+%2.03)’ 
ULF power fmz? 0.64 (0.48-O 87v o&t (0.fr9-t.lal 1.02 (0.70-1.49) 
RR mteTyal (mr) I.07 (I.&i-l.iO)$ I II (1 w-! 17!1 I.21 WY-1.28)t 
SD of RRI (ms) 0.87 (0.76-0.98)” 0 w wo-l-1.02~ 0.94 (0.81-1.09) 
RMSSD (mrl 1.21 (0.96-1.521 1.37 11.ON83)’ 1.53 (1.14-2.07)t 
‘p < 0.05. tp < 0.01 and fp c O.Wl compared with placzbn Vducs ai? rnpnssrd 85 geom&c least rquare 
mean value with 95%, confidence intervals in parentheses. hbbwialions as in Table 1. 
T&e 3. Effect of Atenolol and Mstoprolol on Heart Rate Variability in IS F&nts with Cwaxuy 
Artery Disease (daytime hours) 
AtQlOlOl Melopmtd Placcb AtUenoloWhccb WCtopwMlFkcebo 
HF power (ms? 316 292 IX 1.77 (l.JF-2.36)’ 1.60 tt.zM.i8lt 
LF power (ms’l 579 161 497 1.17 (0.90-1.51) I.13 (0.88-1.46~ 
VLF power tms*) 2.648 2.249 I.wnJ ,.a (1.34-2.05)’ 1.41 (3.14-1.7631 
ULF paver (ms? 728 569 403 I81 (I.&2.261” ,..$I l1.12-I.?BN 
RR interval (mrl I.OSI I.03 789 t.3; (1.26-1.41,’ 130 (1.23-1.38)’ 
SD af RRl (mr) 98 92 78 I.26 (1.12-1.42)* l.IS(I.OFI.JZl# 
RMSSD Cs) 1.319 I.186 II! LB5 (I.4F?.41)? 1.67(1.!5-2.16)’ 
‘p < 0.001. tp < 0.01 and tp < U.05 con&wed Hith placebo. Vvlucr zrc erprcned as least squat rilean value 
wih 952 mntidcncc intervals in parcnlhercr. Abbrwiatmw as 14 Gble 1. 
T&k 4. Effecl of Atenolol and Metoprrrlol on Heart Rale Vanability in IS Patients with Coronary 
Artery Disease @ighltime hours) 
-- 
Atclmlol Mttoirmlal Plsceba !\l~~0lUUPlK&J h[~lOLdOUFlt3C~bo 
HF pow Imszl 423 474 29s ,.a ll.07-1.92)’ 1.61 (1.20-2.Wt 
LF power (ms*) 965 94Y 717 1.X ll.lu-1.75)’ I.32 (1.6z-l.72)* 
MF pwcr (ms’l 2.968 3.115 2.192 1.24 ll.co-1.53) I.11 (1.06-1.621’ 
ULF power (ms? 451 so7 405 I.11 lU.87-1.431 I.25 (0.97-I .6l) 
RR intcrvnl (msl I.IU l.lSl 917 l.lS!! !O-I.?lIf I.,8 (1.KI.240 
SD of RRI (ms) 85 83 73 1.17(1.0~1.33)” I.15 (1.01-1.30)’ 
RMSSD lms) 1.W I.661 I.072 I.48 [l.l?-1,94)t 1.55 (I.IB-Z.M)? 
l p c 0.0s. tp < 0.01 and $p < O.WI compared with placebo. Values are exprrssed as least rq”nm mean valx 
aiti 95% coafidcncc intervals in pyendescs. Abbreviations as in Table I. 
Takk 5. Effect of Morning Arousal and Getting Up on the Frequency and Time Domain Indexes of 
Heart Rate Variability in 18 Subjects with Coronary Artery Disease 
Atcnolol Metopmlol PlW+J AtcnolollPlaccbo MelaprolollPI~ebo 
HF powr 
Bcfotv amuspl Ims? 4% 514 41 I.21 (0.82-1.821 1.27 to.&- 1.87) 
Mu arousal (ms’) 495 SI6 322 I (1.01-2.33)* 1.59 (1 .W-2.42)’ 
After@r~a up (ms’) 331 289 216 0.23 (I. 10-2.14)’ 1.34 (0.9~1.85) 
RMSSD 
&fore amusal 6) I.861 I .806 1.3% I.34 (0.92-1.94) 1.29 (0.90-I X7) 
After arousal (ms) I.799 I.805 1.190 I.51 ll.Ol-2.26)* 1.52 (1.01-2.29)” 
Afler getting “Q lmn) I.274 I.131 848 1.50tl.12-2.01)t 1.33 ll.Ol-1.773’ 
l p < 0.05 and tp c 0.01 compamd with placebo. Valutr are least square mean value with 95% confidence 
intrrvalr in parenthew. Befure amwl = 3Cmin pertad before arousal: After arousal = 3C-min period in a supine 
position after arousal; Alkrgetting up = JC-min period after getting up. Abbreviations as in Table I. 
T&e C. Effect of Morning Amusal on the High Frequency Power 
of&art Rate Variabilily in IS Subjcclr with timnary Artery 
Discare (quotient alter arwaaVbefore arousal) 
ference of normal RR intervals. which is considered to 
reflect parasympathetic activity (4). However, reduction of 
the average heart rate itself (i.e.. increase in the mean RR 
intervals) may result in increases in both the time aad 
freoaencv domain measures of KR interval vatiabilitv. Thus. 
the’obse-wed beta-blockerinduced changes of v&ability 
indexes may be due to increased vagal tone, reduced sym- 
pathetic beta-receptor stimulation or a combinatiw of the 
two. The present findings of equal elects of metopmlol and 
atenolol on heart rs. Ad high frcqucncy power suggest that 
these two beta-blockers with diierent liwphilicitv elicited 
similar changes of cardiac vagabsympat~et~c b&w 
Study bnplicatbns. The existence of a distinct relation 
bctwecn heart rate variability and cardiac death has been 
found &3). II is a challenge to And a phanaacologic inter- 
vention that augments heart rate variability attd thereby 
beneficial. Tbe results with calcium channel blockers and 
classlCantiarrbythmic drags have beendisappointingin this 
respect. Our results showed that bewblwkers improve 
heart rate variability significantly over the long term in 
patients with coronary artery disease. Enhanced heart rate 
variability with beta-blockers may be one of the beneRcial 
mechanisms of beta-blockers in ischemic heart disease. 
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